Oncternal Therapeutics

Company profile

About

Oncternal Therapeutics (NASDAQ:ONCT) is a biopharmaceutical company dedicated to developing innovative therapies for cancer treatment with a focus on addressing unmet medical needs. With an aim to extend and enhance the lives of patients suffering from cancer, Oncternal is currently engaging in several promising projects, including the development of targeted therapies that leverage the latest advancements in oncology research. The company's pipeline showcases a diverse range of investigational drugs, each designed to target specific mechanisms involved in the growth and spread of cancerous cells. Objectives at Oncternal include progressing clinical trials to eventually bring new, effective cancer treatments to market, improving patient outcomes, and establishing partnerships to enhance research and development capabilities.

Snapshot

1997Year founded

29Employees

San Diego, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

San Diego, US

Products and/or services of Oncternal Therapeutics

Cirmtuzumab, a ROR1 monoclonal antibody targeting chronic lymphocytic leukemia, mantle cell lymphoma, and breast cancer.
TK216, a small molecule ETS-family transcription factor inhibitor for Ewing sarcoma.
ROR1 CAR-T therapies, focusing on innovative chimeric antigen receptor T-cell therapies for solid tumors and hematologic cancers.
Zilovertamab vedotin, an antibody-drug conjugate targeting ROR1-expressing tumors.
ONCT-216, targeting B-cell malignancies and certain solid tumors with a focus on developing next-generation inhibitors.
Collaborative research to identify and advance novel cancer therapeutic candidates, emphasizing partnerships with academia and industry.